Arcus Biosciences and Gilead Sciences have reported promising Phase III results from their ARC-10 study of domvanalimab and ...

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

Dr. Cohen-Dayag added, "Our partner, AstraZeneca, continued to advance development of rilvegostoming, their PD-1/TIGIT bispecific of which the TIGIT component is derived from COM902. In September 2024 ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Setrusumab receives Breakthrough Therapy designation from the FDACash of $80.5 million as of September 30, 2024, expected to fund operations into ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the beleaguered ...

Just last month, Bristol-Myers Squibb paid $200 million upfront for rights to a TIGIT drug developed by Agenus called AGEN1777 in a deal that could be worth up to $1.56 billion, while last year ...

Arcus Biosciences (NYSE:RCUS – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at ...

Arcus Biosciences Inc (RCUS) reports robust financial health and strategic advancements in late-stage trials, despite facing ...

Setrusumab receives Breakthrough Therapy designation from the FDA Cash of $80.5 million as of September 30, 2024, expected to fund operations into 2027 LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo ...

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – ...